Corporate Membership

Corporate Membership Opportunities with AAKP

The American Association of Kidney Patients Corporate Partners program is an industry opportunity to support the mission of AAKP and assist the organization in meeting its goals of advocating on behalf of the kidney patient community, providing educational information to patients and their families at all stages of kidney disease, and developing a community that encourages each patient to be an active and informed member of his/her health care team.  A corporate membership allows our industry partners to demonstrate their commitment to helping to improve the quality of education, care, and the life of patients and their care partners. To learn more about Corporate Membership, please contact: Diana Clynes, Director of Programs and Services, at dclynes@aakp.org or (800)-749-2257

Pioneer Members:

amg_amg_zblulogo_1

At Amgen, we are both students and teachers of biology. Amgen brings together many of the very best scholars, scientists and professionals. We are united steadfastly focused on a single mission – helping patients. It’s what drives us to push the boundaries of science, to transform medicine. We dedicate our days to turning the tide on serious, life-interrupting illnesses – to make a positive difference for our families, our friends and our communities. Before we attack a disease, our researchers study it closely – watching the body’s most subtle changes, exploring its mechanisms in new ways to better understand the causes of disease. Over decades, this has given us deep expertise in biotechnology, mastering the complex art and science of engineering and manufacturing medicines through the use of living cells. Now, Amgen is at the forefront of a new biocentury. Learn more about Amgen, Inc.

baxter-100

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care. Learn more about Baxter International Inc.

fkc-1-x-150

At Fresenius Kidney Care, we’re passionately committed to helping people with chronic kidney disease (CKD) and end stage renal disease (ESRD) lead fuller, more active and vibrant lives. As a division of Fresenius Medical Care North America (FMCNA), we’re part of a network of companies dedicated to one mission: providing superior care that improves the quality of life for every patient, every day. With access to the vast resources of our global parent company, Fresenius Medical Care AG & Co. KGaA, the world’s leading innovator in kidney care and the largest provider of dialysis products and services, we’re uniquely equipped to provide comprehensive quality care to all of our patients. From state-of-the-art dialysis equipment to the world’s most advanced dialysis treatment services and patient support services, FMCNA helps nearly 200,000 people with CKD and ESRD improve their lives every day. At the end of each day, over 67,000 FMCNA employees share the same singular commitment of providing the best care to everyone we treat, wherever they may be—at home, in center, in the hospital or at the physician’s office. Learn more about Fresenius.

keryx-biopharmaceuticals-logo

Keryx Biopharmaceuticals, Inc., with headquarters in Boston, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. Learn more about Keryx.

relypsa-web

Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigms. Today, we have more than 400 employees united by a passion for improving people’s lives. Our unique technology platform includes a proprietary high-throughput chemistry process, enabling us to efficiently explore thousands of potential polymer medicines for each disease we seek to address. Learn more about Relypsa.

Supporting Members:

logo-blue-pulse-data-1-x-1-150

pulseData is on a mission to eliminate predictable and preventable sickness. Health systems use our artificial intelligence and machine learning products to predict the future, targeting care efforts to improve outcomes patients at risk of acute events.  Learn more about pulseData.